Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer's disease patients
Jazyk angličtina Země Francie Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
21085906
DOI
10.1007/s12603-010-0325-1
PII: S1279-7707(23)02447-8
Knihovny.cz E-zdroje
- MeSH
- Alzheimerova nemoc krev MeSH
- CD antigeny krev MeSH
- dospělí MeSH
- ELISA MeSH
- endoglin MeSH
- lidé MeSH
- pečovatelské domovy MeSH
- receptory buněčného povrchu krev MeSH
- referenční hodnoty MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- transformující růstový faktor beta krev MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- CD antigeny MeSH
- endoglin MeSH
- ENG protein, human MeSH Prohlížeč
- receptory buněčného povrchu MeSH
- transformující růstový faktor beta MeSH
OBJECTIVES: Senescence of the immune system and of endothelial cells can contribute to age-dependent vascular and neurodegenerative disorders including Alzheimer's disease. The aim of this study is an assessment of putative relationships of serum levels of transforming growth factor beta (TGFβ) and soluble endoglin (sCD105) and neurodegeneration, and of changes of these molecules in the course of ageing. DESIGN: The subjects of the study consisted of three groups, the first one was 63 otherwise healthy middle - aged participants, 31 females, 32 males, of average age 35 years. The second group was formed by 58 healthy, self-dependent inhabitants of nursing homes, 44 females and 14 males, average age 83.5 years. The third group comprised of 129 Alzheimer's disease patients, 86 females, 43 males, of average age 80 years, with MMSE score that ranged from 16 to 20. MEASUREMENT: Serum levels of TGF beta and soluble endoglin were measured by the ELISA method in samples of peripheral blood using commercial kits. RESULTS: The serum level of TGFβ was 34,339 ± 6,420 pg/ml in the healthy younger group, 37,555 ± 11,944 pg/ml in the healthy seniors, and 29,057 ± 11,455 pg/ml in Alzheimer's disease patients. Compared to healthy seniors, the serum level of TGFβ was significantly decreased in Alzheimer's disease patients (p < 0.01). The serum level of endoglin were 4.88 ± 0.95 μg/ml in the healthy younger group; 6.11 ± 1.38 μg/ml in healthy seniors, and 7.20 ± 1.72 μg/ml in patients with Alzheimer's disease, respectively. The serum level of endoglin was significantly higher (p < 0.001) in senescent healthy persons compared to the younger control group. When compared with healthy seniors, patients with Alzheimer's disease had significantly elevated (p < 0.001) serum level of endoglin. CONCLUSIONS: Decreased levels of TGF β in Alzheimer's disease may result in impairment of cerebral circulation reflected in the increased endoglin levels. These findings may indicate involvement of the immune system in Alzheimer's disease pathogenesis.
Zobrazit více v PubMed
Neurobiol Aging. 2000 May-Jun;21(3):383-421 PubMed
Curr Alzheimer Res. 2006 Dec;3(5):505-13 PubMed
Int Immunopharmacol. 2005 Dec;5(13-14):1771-82 PubMed
Neuropathology. 2006 Aug;26(4):298-306 PubMed
Mult Scler. 1999 Apr;5(2):69-73 PubMed
FASEB J. 2000 Jan;14(1):55-64 PubMed
J Biochem Mol Biol. 2005 Jan 31;38(1):1-8 PubMed
Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):121-8 PubMed
Scand J Clin Lab Invest. 2008;68(4):348-51 PubMed
Am J Pathol. 2000 Jan;156(1):139-50 PubMed
Clin Cancer Res. 2001 Mar;7(3):524-32 PubMed
Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1712-20 PubMed
Rheumatology (Oxford). 2008 Jul;47(7):972-5 PubMed
Circulation. 2006 Nov 21;114(21):2288-97 PubMed
J Cereb Blood Flow Metab. 2004 Feb;24(2):237-44 PubMed
J Cell Biochem. 2007 Dec 15;102(6):1375-88 PubMed
Angiogenesis. 2008;11(1):79-89 PubMed
